Suspended PHASE4 INTERVENTIONAL 1-arm NCT01320501

Experience of Erlotinib in Patients With Advanced Non-Small Cell Lung Cancer (REALME)

Real Life Experience of Erlotinib in Patients With Advanced Non-Small Cell Lung Cancer in the Middle Eastern Countries (REALME)

Sponsor: National Guard Health Affairs

Conditions Non-small Cell Lung Cancer Metastatic

Interventions Erlotinib

Updated 5 times since 2017 Last updated: May 12, 2016 Started: Oct 31, 2009 Primary completion: Aug 31, 2016 Completion: Aug 31, 2016

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Suspended

Difficulty in enrolling patients

This PHASE4 trial investigates Non-small Cell Lung Cancer Metastatic and is currently suspended. National Guard Health Affairs leads this study, which shows 5 recorded versions since 2009 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Suspended PHASE4
Jul 2024 — Sep 2024 [monthly]

Suspended PHASE4
Jan 2021 — Jul 2024 [monthly]

Suspended PHASE4
Jun 2018 — Jan 2021 [monthly]

Suspended PHASE4
Jan 2017 — Jun 2018 [monthly]

Suspended PHASE4

First recorded

Oct 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

National Guard Health Affairs

Data source: National Guard Health Affairs

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Riyadh, Saudi Arabia